Citius Pharmaceuticals, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Citius Oncology reported 792 LYMPHIR units sold to U.S. wholesalers in Q4 2026 (ended September 30), a 120% increase from 360 units in Q3 2026. Institutional ordering reached 54 centers as of filing date (up from 44 on August 14, 2026), with 950 vials ordered by prescribing centers during Q4. The company states it is "more than halfway" to a goal of 100 priority institutions on formulary by calendar year-end 2026. Revenue recognition occurs on wholesaler fulfillment, not end-user orders.
Why this rating
Early-stage product launch showing strong unit growth and institutional uptake. Material relative to $11.4M market cap; validates commercialization execution but financial impact unquantified pending full FY 2026 results in December 2026.
Price action (we called it positive)
before filing · preread $0.45 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.